Houston-based Plus Therapeutics has signed an agreement with Ephemeral Technologies to develop an AI platform designed to integrate and analyze longitudinal therapeutic, diagnostic, and bioinformatic data across the company's central nervous system (CNS) oncology programs.
Ephemeral, founded by former co-heads of Palantir Technologies' U.S. healthcare business, will work with Plus to assess and implement AI-enabled data infrastructure to support the integration and analysis of complex CNS oncology datasets, the companies said. No financial terms were disclosed.
Plus Therapeutics is a clinical-stage pharmaceutical company developing radiopharmaceutical therapies for CNS cancers, with lead programs in leptomeningeal metastases and recurrent glioblastoma.
